Molecular Biometrics to Open Research and Development Facility in Montreal
News Apr 20, 2007
Molecular Biometrics, LLC, has announced the opening of a research and development facility in Montreal, Quebec. Molecular Biometrics Canada, ULC, will operate and manage the facility.
James Posillico, Ph.D., Chief Executive Officer of Molecular Biometrics, commented, "It was a propitious time to set-up a research facility in Montreal to further develop our fertility product portfolio and to initiate new research in additional therapeutic fields, including maternal-fetal medicine and neurodegenerative diseases. There is a highly experienced pool of scientific talent for us to draw upon in Montreal, and the region has a long history of supporting breakthrough biomedical research."
Dr. Posillico continued, "Molecular Biometrics Canada will also serve as the company's base of commercial operations to serve the Canadian market with our products. Our Canadian facility will focus on the development and enhancement of the Company's novel technology platform which is based on breakthrough metabolomic, bioinformatics and biospectroscopy sciences.”
“This technology is able to identify specific biomarkers in a given biological sample and convert the information into a novel 'metabolomic profile' that is indicative of health or disease."
The analysis is performed using a small, low-cost and easy-to-use instrument that has been engineered to integrate the company's technology platform. Single use, disposable sample cells, that are manufactured in Montreal, are used to hold and analyze a given specimen. The same instrument design can be utilized for testing in multiple therapeutic fields, as well as in pharmacodiagnostics for drug discovery and development.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE